If you have been reading about lactam bridge and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4R agonist | Subtype most often linked to behavioural effects |
| Other reported targets | MC1R, MC3R, MC5R | Activity is not selective for a single subtype |
| Endogenous ligand class | Melanocortin peptides | Alpha-MSH and ACTH act on the same family |
| Peptide architecture | Cyclic heptapeptide | Lactam bridge between the aspartate and lysine residues |
| Central action | Inferred from animal models | Not directly measured in the human brain |
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
=== Preparation === This compound is prepared by oxidation of 4-aminodimethylaniline in the presence of sodium thiosulfate to give the quinonediiminothiosulfonic acid, reaction with dimethylaniline, oxidation to the indamine, and cyclization to give the thiazine:
== Synthesis == Because ELPs are protein-based biopolymers, synthesis involves manipulation of genes to continually express the monomeric repeat unit. Various techniques have been employed in the production of ELPs of various sizes, including unidirectional ligation or concatemerization, overlap extension polymerase chain reaction (OEPCR), and recursive directional ligation (RDL). Also, ELPs can be experimentally modified through conjugation with other polymers or through SpyTag/SpyCatcher reaction, allowing for the synthesis of copolymers with unique morphology.
G-protein-coupled receptor (GPCR) A large family of membrane receptors that activate intracellular signaling pathways through G-proteins. GPCRs are critical in neurotransmission, hormone signaling, and sensory perception. Granule cell A small neuron found in the cerebellum, olfactory bulb, and dentate gyrus of the hippocampus. Granule cells play important roles in sensory and motor information processing. Granulomatosis with polyangiitis An autoimmune disease that can affect the central nervous system, sometimes causing neuropathy, headaches, or stroke-like symptoms due to vascular inflammation. Grasp reflex A primitive reflex seen in infants where touching the palm induces the hand to close. Persistence in adults may indicate frontal lobe damage. Gray matter Brain tissue composed primarily of neuronal cell bodies, dendrites, and unmyelinated axons. It is responsible for information processing and synaptic transmission. Growth cone A dynamic, motile structure at the tip of a developing axon or dendrite that guides neuronal growth by sensing molecular cues in the environment. Growth factor A naturally occurring protein that stimulates cell growth, differentiation, and survival. Examples include BDNF, NGF, and EGF in neural development and repair. Gustatory cortex The brain area responsible for processing taste information, primarily located in the insular and frontal opercular regions. Gyri (singular gyrus) The raised ridges or folds of the cerebral cortex. They increase the brain’s surface area and are separated by sulci (grooves).
The dominant material for contact lenses are acrylate-siloxane hydrogels. They have replaced hard contact lenses. One of their most attractive properties is oxygen permeability, which is required since the cornea lacks vasculature.
Yeast is used in winemaking, where it converts the sugars present (glucose and fructose) in grape juice (must) into ethanol. Yeast is normally already present on grape skins. Fermentation can be done with this endogenous "wild yeast", but this procedure gives unpredictable results, which depend upon the exact types of yeast species present. For this reason, a pure yeast culture is usually added to the must; this yeast quickly dominates the fermentation. The wild yeasts are repressed, which ensures a reliable and predictable fermentation. Most added wine yeasts are strains of S. cerevisiae, though not all strains of the species are suitable. Different S. cerevisiae yeast strains have differing physiological and fermentative properties, therefore the actual strain of yeast selected can have a direct impact on the finished wine. Significant research has been undertaken into the development of novel wine yeast strains that produce atypical flavour profiles or increased complexity in wines. The growth of some yeasts, such as Zygosaccharomyces and Brettanomyces, in wine can result in wine faults and subsequent spoilage. Brettanomyces produces an array of metabolites when growing in wine, some of which are volatile phenolic compounds. Together, these compounds are often referred to as "Brettanomyces character", and are often described as "antiseptic" or "barnyard" type aromas. Brettanomyces is a significant contributor to wine faults within the wine industry. Researchers from the University of British Columbia, Canada, have found a new strain of yeast that has reduced amines.
Sources: en.wikipedia.org
E-cigarette makers do not fully disclose information on the chemicals that can be released or synthesized during use. The chemicals in the e-cigarette vapor can be different than with the liquid. Once vaporized, the ingredients in the e-liquid go through chemical reactions that form new compounds not previously found in the liquid. Many chemicals including carbonyl compounds such as formaldehyde, acetaldehyde, acrolein, and glyoxal can inadvertently be produced when the nichrome wire (heating element) that touches the e-liquid is heated and chemically reacted with the liquid. Acrolein and other carbonyls have been found by in e-cigarette vapors that were created by unmodified e-cigarettes, indicating that formation of these compounds could be more common than previously thought. A 2017 review found "Increasing the battery voltage from 3.3 V to 4.8 V doubles the amount of e-liquid vapourized and increases the total aldehyde generation more than threefold, with acrolein emission increasing tenfold." A 2014 study stated that "increasing the voltage from 3.2 to 4.8 V resulted in a 4 to >200 times increase in the formaldehyde, acetaldehyde, and acetone levels". The amount of carbonyl compounds in e-cigarette aerosols varies substantially, not only among different brands but also among different samples of the same products, from 100-fold less than tobacco to nearly equivalent values. The propylene glycol-containing liquids produced the most amounts of carbonyls in e-cigarette aerosols. Propylene glycol could turn into propylene oxide when heated and aerosolized.
DNA barcoding A method of taxonomic identification in which short DNA sequences from one or more specific genes are isolated from unidentified samples and then aligned with a genomic reference library in order to uniquely identify the species or other taxon from which the samples originated. The sequences used in the comparison are chosen carefully from genes that are both widely conserved and that show greater variation between species than within species, e.g. the cytochrome c oxidase gene for eukaryotes or certain ribosomal RNA genes for prokaryotes. These genes are present in nearly all living organisms but tend to evolve different mutations in different species, such that a unique sequence variant can often be linked to one particular species, effectively creating a unique identifier akin to a retail barcode. DNA barcoding allows unknown specimens to be identified from otherwise indistinct tissues or body parts, where identification by morphology would be difficult or impossible, and the library of organismal barcodes is now comprehensive enough that even organisms previously unknown to science can often be phylogenetically classified with confidence. The simultaneous identification of multiple different species from a mixed sample is known as metabarcoding.
=== Acrylamide controversy === Heating a mixture of asparagine and reducing sugars or other source of carbonyls produces acrylamide in food. These products occur in baked goods such as French fries, potato chips, and toasted bread. Acrylamide is converted in the liver to glycidamide, which is a possible carcinogen.
(This formula is used for example in describing the measuring principle of a dasymeter and of hydrostatic weighing.) Example: If you drop wood into water, buoyancy will keep it afloat. Example: A helium balloon in a moving car. When increasing speed or driving in a curve, the air moves in the opposite direction to the car's acceleration. However, due to buoyancy, the balloon is pushed "out of the way" by the air and will drift in the same direction as the car's acceleration. When an object is immersed in a liquid, the liquid exerts an upward force, which is known as the buoyant force, that is proportional to the weight of the displaced liquid. Consequently, the net force acting on the object is equal to the difference between the weight of the object, or 'down' force, and the weight of the displaced fluid, or 'up' force. Equilibrium, or neutral buoyancy, is achieved when these two weights and thus forces are equal.
Sources: en.wikipedia.org
The vocalisations of emus mostly consist of various booming and grunting sounds. The booming is created by the inflatable throat pouch; the pitch can be regulated by the bird and depends on the size of the aperture. Most of the booming is done by females; it is part of the courtship ritual, is used to announce the holding of territory and is issued as a threat to rivals. A high-intensity boom is audible 2 kilometres (1.2 mi) away, while a low, more resonant call, produced during the breeding season, may at first attract mates and peaks while the male is incubating the eggs. Most of the grunting is done by males. It is used principally during the breeding season in territorial defence, as a threat to other males, during courtship and while the female is laying. Both sexes sometimes boom or grunt during threat displays or on encountering strange objects. On very hot days, emus pant to maintain their body temperature. Their lungs work as evaporative coolers and, unlike some other species, the resulting low levels of carbon dioxide in the blood do not appear to cause alkalosis. For normal breathing in cooler weather, they have large, multifolded nasal passages. Cool air warms as it passes through into the lungs, extracting heat from the nasal region. On exhalation, the emu's cold nasal turbinates condense moisture back out of the air and absorb it for reuse. As with other ratites, the emu has great homeothermic ability, and can maintain this status from −5 to 45 °C (23 to 113 °F). The thermoneutral zone of emus lies between 10 and 30 °C (50 and 86 °F).
=== Solo & local === Since the diffusion of Ca2+ in the cell is spatially restricted, Ca2+ released by a channel does not travel far from its source (the channel mouth) — model estimates are in the 50 nm range. Therefore, the small total amount of Ca2+ released from lysosomal channels will form locally high [Ca2+] domains around the cytosolic face of lysosomal Ca2+ channels. By strategic placement of Ca2+-sensitive decoding proteins within these domains (e.g. in a complex with the channel), local Ca2+ signals can stimulate Ca2+-dependent events — crucially, even in the absence of a global cytosolic Ca2+ signal. This is the modality when lysosomes are acting on their own. The NAADP/TPC axis has been reported to exhibit such signal compartmentation, such local Ca2+ signalling, in different physiological settings. In other words, this local modality can explain why some processes are driven uniquely by NAADP/TPCs rather than other Ca2+ signalling pathways. For example, NAADP/TPCs are unique drivers of cell killing by Cytotoxic T cells. Similarly, phagocytosis via the Fc receptor in the macrophage is driven only by highly local Ca2+ domains generated by NAADP/TPCs (whereas the global ER Ca2+ signals play no role). This unique dependence is not restricted to immune cells, but is also observed in neurons during long-term potentiation, and neuronal differentiation. Angiogenesis is another NAADP/TPC-dependent pathway.
=== Acoustic lysis === This method uses ultrasonic waves to generate areas of high and low pressure which causes cavitation and in turn, cell lysis. Though this method usually comes out clean, it fails to be cost effective and consistent.
Sources: en.wikipedia.org
Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.
It is not classified as a vasodilator, and its proposed site of action is the central nervous system rather than peripheral vessels. Some trial participants show small transient blood pressure changes. Whether those changes arise centrally or through another route remains an open question.
Most evidence comes from animal models and from indirect human outcomes such as self-reported desire. Direct measurements of receptor occupancy or signalling in the human brain are not available. Published reviews therefore present a plausible pathway rather than a confirmed sequence of events.
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.